2,028,154 Shares in CVS Health Corporation $CVS Acquired by Nykredit A S

Key Points

• Nykredit A S acquired 2.03 million CVS Health shares worth approximately $209.8 million, making CVS about 0.6% of its portfolio. Institutional investors and hedge funds collectively own 80.66% of CVS.
• CVS reported quarterly earnings of $2.58 per share, exceeding the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. The company maintained fiscal 2026 EPS guidance of $7.90–$8.10.
• Despite the stock’s recent decline, analysts remain generally positive, with a consensus “Moderate Buy” rating and an average price target of $107.24; CVS also offers a $2.66 annualized dividend yielding about 2.9%.

Nykredit A S purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,028,154 shares of the pharmacy operator's stock, valued at approximately $209,813,000. CVS Health makes up approximately 0.6% of Nykredit A S's holdings, making the stock its 22nd largest position. Nykredit A S owned approximately 0.16% of CVS Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of CVS. Parkside Financial Bank & Trust raised its holdings in CVS Health by 7.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 5,211 shares of the pharmacy operator's stock worth $539,000 after buying an additional 365 shares during the period. Range Advisory LLC acquired a new position in shares of CVS Health in the second quarter worth about $544,000. Brown Lisle Cummings Inc. increased its position in shares of CVS Health by 8.4% in the second quarter. Brown Lisle Cummings Inc. now owns 14,858 shares of the pharmacy operator's stock worth $1,537,000 after acquiring an additional 1,150 shares in the last quarter. Amundi raised its holdings in shares of CVS Health by 2.1% during the second quarter. Amundi now owns 7,525,080 shares of the pharmacy operator's stock valued at $778,469,000 after acquiring an additional 154,142 shares during the period. Finally, Groupe la Francaise purchased a new stake in shares of CVS Health in the 2nd quarter valued at approximately $5,175,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 1.6%

CVS Health stock opened at $90.25 on Friday. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market cap of $115.43 billion, a PE ratio of 23.88, a P/E/G ratio of 0.89 and a beta of 0.59. The firm's 50 day moving average price is $99.09 and its two-hundred day moving average price is $91.31.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same period in the prior year, the business posted $1.81 earnings per share. CVS Health's revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's dividend payout ratio is presently 70.37%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Mizuho raised their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Monday, June 8th. BMO Capital Markets set a $112.00 target price on CVS Health in a report on Wednesday, September 9th. Wall Street Zen cut CVS Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 12th. Truist Financial lifted their price target on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Finally, UBS Group dropped their price target on CVS Health from $126.00 to $118.00 and set a "buy" rating on the stock in a research report on Thursday, September 3rd. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $107.24.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna is streamlining oncology prior authorizations. CVS Health’s insurance unit plans to reduce cancer-treatment approvals to one early medical prior authorization, with bundled processes expanding to eligible Medicaid members and across all Aetna businesses in 2027. The move could reduce administrative costs, ease provider friction and accelerate patient access to treatment. Reuters article Aetna press release
• Positive Sentiment: Digital-twin technology may improve execution. CVS is using digital simulations to test changes and make operational decisions more quickly and confidently. Although the financial benefit is not quantified, the technology could support efficiency and better implementation across the company. Digital twins article
• Neutral Sentiment: Valuation appears attractive but carries execution risk. An investment commentary says CVS trades below Wall Street price targets and at an inexpensive forward valuation, while cautioning that the bullish consensus could prove vulnerable if business conditions deteriorate. Valuation analysis
• Neutral Sentiment: CVS also published women’s-health information about polyendocrine metabolic ovarian syndrome and highlighted an affordable-housing project. These initiatives may strengthen its social and healthcare profile but are unlikely to materially affect near-term earnings. Women’s health article Affordable housing article

CVS Health Profile

CVS Health Corporation is an American health care company headquartered in Woonsocket, Rhode Island. Founded in 1963 as Consumer Value Stores, the company has expanded from a chain of retail pharmacies into an integrated health care organization serving consumers, employers, health plans, government programs and health care providers.

CVS Health operates through several major businesses. Its Health Care Benefits segment, anchored by Aetna, provides health insurance products and related services for employers, individuals, Medicare and Medicaid members.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.